male Schistosoma mansoni cercariae

PreclinicalBiologic

male Schistosoma mansoni cercariae is one of 5 biologic programs targeting Schistosomiasis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SchistosomiasisActive, not recruiting

SchistosomiasisPreclinical

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Schistosomiasis

#DrugCompanyPhaseTrials

Biltricide

Bayer

Approved

7 2

Daraprim

FFondazione Matilde Tettamanti Menotti De Marchi Onlus

Artesunate

Ferrous Sulphate

1 5

male Schistosoma mansoni cercariae

LLeiden University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Schistosomiasis1 trial

Single-sex Controlled Human Schistosomiasis Infection: Safety and Dose Finding

Completed·LLeiden University·N/A·NCT02755324·17 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for male Schistosoma mansoni cercariae. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — male Schistosoma mansoni cercariae compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for male Schistosoma mansoni cercariae. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Leiden University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: LLeiden University

male Schistosoma mansoni cercariae

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Schistosomiasis1 trial

References

Drug Info

Quick Facts

Related News